Dr Subbiah On Outcomes With Larotrectinib In Trk Fusion-Positive Solid Tumors

Dr Subbiah on Outcomes With Larotrectinib in TRK Fusion–Positive Solid Tumors

Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors

Targeted Oncology

Vivek Subbiah, MD, describes solid tumor tests for RET fusion and similarities to other therapies

Larotrectinib, a TRK inhibitor for patients with solid tumors

Larotrectinib Is Well-Tolerated in Metastatic Solid Tumors

Targeted Oncology

Larotrectinib for Solid Tumors With NTRK Gene Fusions

TRK Inhibition: Personal Experience With Larotrectinib

Larotrectinib for Patients With TRK Fusion-Positive CNS Tumors

Pralsetinib for Advanced or Metastatic RET-Altered Thyroid Cancer with Dr. Vivek Subbiah

THANC Foundation

Larotrectinib in NTRK Fusion-Positive Lung Cancer

Targeted Oncology

Larotrectinib in patients with TRK fusion salivary gland tumours

The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers

Dr. Subbiah on the Importance of Tivozanib in RCC

Dr. Vivek Subbiah discusses the novel lesion selection tool reported in JIPO by Xu et al

Journal of Immunotherapy and Precision Oncology

Favorable Safety Profile in Novel TRK Inhibitor

Larotrectinib for NTRK Fusions: Patient Selection

Positive Larotrectinib Data for TRK Fusion Cancer Presented at ESMO

Pharmacy Times TV

Intracranial activity of selpercatinib in RET fusion positive NSCLC

Other Approaches to TRK-Fusion Cancers